Relmada Therapeutics (RLMD) HAP Data Significantly Improves Commercial Outlook - Analyst

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/12/2026


Go back to Relmada Therapeutics (RLMD) HAP Data Significantly Improves Commercial Outlook - Analyst

Relmada Therapeutics Announces Top-Line Results of Study Evaluating REL-1017 vs Oxycodone for Abuse Potential

July 27, 2021 7:35 AM UTC

NEW YORK, July 27, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), announced today top-line results of the human abuse potential (HAP) study with REL-1017, a novel NMDA receptor (NMDAR) channel... More